Acute Myelogenous Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Acute Myelogenous Leukemia > What Your Doctor is Reading About Acute Myelogenous Leukemia > Review Articles

Review Articles

1. Molecular characterization of acute myeloid leukemia and its impact on treatment.

Author: Frankfurt O; Licht JD; Tallman MS;
Institution: Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA. o-frankfurt@northwestern.edu
Journal: Curr Opin Oncol. 2007 Nov;19(6):635-49.
Abstract URL: Click here to view abstract

2. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.

Author: Valcarcel D; Martino R; Valcarcel D; Martino R;
Institution: Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. dvalcarcel@santpau.es
Journal: Curr Opin Oncol. 2007 Nov;19(6):660-6.
Abstract URL: Click here to view abstract

3. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.

Author: Shaw BE; Russell NH;
Institution: Section of Haemato-Oncology, Royal Marsden Hospital, Surrey, UK. bshaw@doctors.org.uk
Journal: Bone Marrow Transplant. 2008 Mar;41(5):495-503. Epub 2007 Oct 22.
Abstract URL: Click here to view abstract

4. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.

Author: Cheuk AT; Guinn BA;
Institution: Department of Haematological Medicine, King's College London School of Medicine, The Rayne Institute, 123 Coldharbour Lane, London, SE5 9NU, United Kingdom.
Journal: Front Biosci. 2008 Jan 1;13:2022-9.
Abstract URL: Click here to view abstract

5. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.

Author: Seedhouse C; Russell N;
Institution: Department of Academic Haematology, University of Nottingham, Nottingham University Hospitals, Nottingham, UK. claire.seedhouse@nottingham.ac.uk
Journal: Br J Haematol. 2007 Jun;137(6):513-29.
Abstract URL: Click here to view abstract

6. Monitoring of minimal residual disease in acute myeloid leukemia.

Author: Kern W; Haferlach C; Haferlach T; Schnittger S;
Institution: MLL Munich Leukemia Laboratory, Munich, Germany. wolfgang.kern@mll-online.com
Journal: Cancer. 2008 Jan 1;112(1):4-16.
Abstract URL: Click here to view abstract

7. Novel strategies for relapsed and refractory acute myeloid leukemia.

Author: Mato AR; Morgans A; Luger SM;
Institution: Abramson Cancer Center and Division of Hematology and Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Journal: Curr Opin Hematol. 2008 Mar;15(2):108-14.
Abstract URL: Click here to view abstract

8. Alternative donor transplants for high-risk acute myeloid leukemia.

Author: Gupta V;
Institution: Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, Canada. vikas.gupta@uhn.on.ca
Journal: Curr Opin Hematol. 2008 Mar;15(2):115-20.
Abstract URL: Click here to view abstract

9. New approaches in acute myeloid leukemia.

Author: Blum W; Marcucci G;
Institution: Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. william.blum@osumc.edu
Journal: Best Pract Res Clin Haematol. 2008 Mar;21(1):29-41.
Abstract URL: Click here to view abstract

10. Consolidation therapy: what should be the standard of care?

Author: Rowe JM;
Institution: Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel. rowe@jimmy.harvard.edu
Journal: Best Pract Res Clin Haematol. 2008 Mar;21(1):53-60.
Abstract URL: Click here to view abstract

11. Older adults: should the paradigm shift from standard therapy?

Author: Estey EH;
Institution: Section of Acute Leukemia and Myelodysplastic Syndrome, Division of Cancer Medicine, MD Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA. eestey@mdanderson.org
Journal: Best Pract Res Clin Haematol. 2008 Mar;21(1):61-6.
Abstract URL: Click here to view abstract

12. Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).

Author: Appelbaum FR;
Institution: Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Avenue North, D5-310, P.O. Box 19024, Seattle, WA 98109-1024, USA. fappelba@fhcrc.org
Journal: Best Pract Res Clin Haematol. 2008 Mar;21(1):85-92.
Abstract URL: Click here to view abstract

13. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Author: Stasi R;
Institution: Regina Apostolorum Hospital, Department of Medical Sciences, Via S. Francesco, 50, 00041 Albano Laziale, Italy. roberto.stasi@uniroma2.it
Journal: Expert Opin Biol Ther. 2008 Apr;8(4):527-40.
Abstract URL: Click here to view abstract

14. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia.

Author: Hamadani M; Awan FT; Copelan EA;
Institution: Division of Hematology & Oncology, Arthur G. James Cancer Hospital, Ohio State University, Columbus, Ohio, USA.
Journal: Biol Blood Marrow Transplant. 2008 May;14(5):556-67.
Abstract URL: Click here to view abstract

15. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

Author: Lekakis L; de Lima M;
Institution: Department of Hematology, Medical Oncology & Blood and Marrow Transplantation, Markey Cancer Center, University of Kentucky, 800 Rose St, Roach Building, Ste 412, Lexington, KY 40536, USA. ljleka2@uky.edu
Journal: Expert Rev Anticancer Ther. 2008 May;8(5):785-98.
Abstract URL: Click here to view abstract

16. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.

Author: Faderl S; Gandhi V; Kantarjian HM;
Institution: Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. sfaderl@mdanderson.org
Journal: Curr Opin Hematol. 2008 Mar;15(2):101-7.
Abstract URL: Click here to view abstract

17. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.

Author: Amadori S; Stasi R;
Institution: Department of Hematology, Tor Vergata University Hospital, Rome, Italy. sergio.amadori@ptvonline.it
Journal: Curr Opin Hematol. 2008 Mar;15(2):95-100.
Abstract URL: Click here to view abstract

18. New molecular concepts and targets in acute myeloid leukemia.

Author: Buzzai M; Licht JD;
Institution: Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Journal: Curr Opin Hematol. 2008 Mar;15(2):82-7.
Abstract URL: Click here to view abstract

19. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.

Author: Loren AW; Porter DL;
Institution: Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA 19104, USA. alison.loren@uphs.upenn.edu
Journal: Bone Marrow Transplant. 2008 Mar;41(5):483-93. Epub 2007 Nov 19.
Abstract URL: Click here to view abstract

20. Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials.

Author: Gleissner B; Schlenk R; Bornhauser M; Berdel WE;
Institution: Department of Medicine I, University Hospital Saarland, Homburg, Germany. beate.gleissner@uniklinikum-saarland.de
Journal: Onkologie. 2007 Dec;30(12):657-62. Epub 2007 Nov 30.
Abstract URL: Click here to view abstract

21. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.

Author: Craddock CF;
Institution: Centre for Clinical Haematology, University Hospital Birmingham NHS Trust, Birmingham, UK. charles.craddock@uhb.nhs.uk
Journal: Bone Marrow Transplant. 2008 Mar;41(5):415-23. Epub 2008 Jan 21.
Abstract URL: Click here to view abstract

22. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.

Author: Sierra J; Martino R; Sanchez B; Pinana JL; Valcarcel D; Brunet S;
Institution: Clinical Hematology Division and Hematopoietic Transplant Program, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. jsierra@santpau.es
Journal: Bone Marrow Transplant. 2008 Mar;41(5):425-37. Epub 2008 Jan 21.
Abstract URL: Click here to view abstract

23. Umbilical cord blood transplantation in adult myeloid leukemia.

Author: Tse WW; Zang SL; Bunting KD; Laughlin MJ;
Institution: Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, Abraham J. and Phyllis Katz Cord Blood Foundation, Center for Stem Cell and Regenerative Medicine, Cleveland, OH 44106-7284, USA.
Journal: Bone Marrow Transplant. 2008 Mar;41(5):465-72. Epub 2008 Feb 4.
Abstract URL: Click here to view abstract

24. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.

Author: Morgan MA; Reuter CW;
Institution: Department of Hematology, Hemostasis and Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. christophreuter@yahoo.com
Journal: Ann Hematol. 2006 Mar;85(3):139-63. Epub 2006 Jan 4.
Abstract URL: Click here to view abstract

25. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.

Author: Oliansky DM; Rizzo JD; Aplan PD; Arceci RJ; Leone L; Ravindranath Y; Sanders JE; Smith FO 3rd; Wilmot F; McCarthy PL Jr; Hahn T;
Institution: Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Journal: Biol Blood Marrow Transplant. 2007 Jan;13(1):1-25.
Abstract URL: Click here to view abstract

26. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia.

Author: Litzow MR;
Institution: Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. Litzow.mark@mayo.edu
Journal: Curr Opin Hematol. 2007 Mar;14(2):130-7.
Abstract URL: Click here to view abstract

27. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.

Author: Baron F; Storb R;
Institution: University of Liege, Liege, Belgium.
Journal: Curr Opin Hematol. 2007 Mar;14(2):145-51.
Abstract URL: Click here to view abstract

28. Alternative donor transplantation in acute myeloid leukemia: which source and when?

Author: Zuckerman T; Rowe JM;
Institution: Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. t_zuckerman@rambam.health.gov.il
Journal: Curr Opin Hematol. 2007 Mar;14(2):152-61.
Abstract URL: Click here to view abstract

29. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.

Author: Greiner J; Dohner H; Schmitt M;
Institution: Tumor Immunology Group, Dept. of Internal Medicine III, Robert-Koch-Str. 8 University of Ulm, 89081 Ulm, Germany.
Journal: Haematologica. 2006 Dec;91(12):1653-61.
Abstract URL: Click here to view abstract

30. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.

Author: Kern W; Estey EH;
Institution: MLL Munich Leukemia Laboratory, Munich, Germany. wolfgang.kern@mll-online.com
Journal: Cancer. 2006 Jul 1;107(1):116-24.
Abstract URL: Click here to view abstract

31. New therapeutic approach for myeloid leukemia: induction of apoptosis via modulation of reactive oxygen species production by natural compounds.

Author: Kizaki M;
Institution: Division of Hematology, Keio University School of Medicine, Tokyo, Japan. makizaki@sc.itc.keio.ac.jp
Journal: Int J Hematol. 2006 May;83(4):283-8.
Abstract URL: Click here to view abstract

32. Monoclonal antibodies for the treatment of acute myeloid leukemia.

Author: Abutalib SA; Tallman MS; Abutalib SA; Tallman MS;
Institution: Section of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL, USA.
Journal: Curr Pharm Biotechnol. 2006 Oct;7(5):343-69.
Abstract URL: Click here to view abstract

33. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.

Author: Deschler B; de Witte T; Mertelsmann R; Lubbert M; Deschler B; de Witte T; Mertelsmann R; Lubbert M;
Institution: Department of Hematology Oncology, University of Freiburg Hugstetterstr. 55, D-79106 Freiburg, Germany.
Journal: Haematologica. 2006 Nov;91(11):1513-22.
Abstract URL: Click here to view abstract

34. Umbilical cord blood transplantation for myeloid malignancies.

Author: Brunstein CG; Baker KS; Wagner JE; Brunstein CG; Baker KS; Wagner JE;
Institution: Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA. bruns072@umn.edu
Journal: Curr Opin Hematol. 2007 Mar;14(2):162-9.
Abstract URL: Click here to view abstract

35. Treatment of acute myeloid leukemia in older patients.

Author: Roboz GJ;
Institution: Weill Medical College of Cornell University and The New York Presbyterian Hospital, 520 East 70th Street, Starr 340A, New York, NY 10021, USA. gar2001@med.cornell.edu
Journal: Expert Rev Anticancer Ther. 2007 Mar;7(3):285-95.
Abstract URL: Click here to view abstract

36. Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.

Author: Thomas X; Dombret H;
Institution: Leukemia Unit, Hematology Department, Edouard Herriot Hospital, Lyon, France. xavier.thomas@chu-lyon.fr
Journal: Hematology. 2007 Feb;12(1):15-28.
Abstract URL: Click here to view abstract

37. Risk factors for acute leukemia in children: a review.

Author: Belson M; Kingsley B; Holmes A;
Institution: Centers for Disease Control and Prevention, National Center for Environmental Health, Division of Environmental Hazards and Health Effects, Health Studies Branch, Atlanta, Georgia 30341, USA. mbelson@cdc.gov
Journal: Environ Health Perspect. 2007 Jan;115(1):138-45.
Abstract URL: Click here to view abstract

38. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.

Author: Quintas-Cardama A; Cortes J;
Institution: University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA.
Journal: Expert Opin Investig Drugs. 2007 Apr;16(4):547-57.
Abstract URL: Click here to view abstract

39. An analysis of current neutropenia therapies, including pegfilgrastim.

Author: Gabrilove JL;
Institution: Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. janice.gabrilove@mssm.edu
Journal: Clin Cornerstone. 2006;8 Suppl 5:S19-28.
Abstract URL: Click here to view abstract

40. Dendritic cell vaccines for leukemia patients.

Author: Schmitt A; Hus I; Schmitt M; Schmitt A; Hus I; Schmitt M;
Institution: Tumor Immunology Group, University of Ulm, Clinic for Internal Medicine III, Robert-Koch-Str. 8, 89081 Ulm, Germany. anita.schmitt@uni-ulm.de
Journal: Expert Rev Anticancer Ther. 2007 Mar;7(3):275-83.
Abstract URL: Click here to view abstract

41. The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes.

Author: Bhatia M; Davenport V; Cairo MS;
Institution: Departments of Pediatrics, Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA.
Journal: Leuk Lymphoma. 2007 Jan;48(1):9-15.
Abstract URL: Click here to view abstract